CEL-SCI Appoints Robert Watson As Chairperson Of The Board

7/8/24 9:21:33 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CVM alert in real time by email

CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board.

Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt instruments.

Get the next $CVM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CVM

Date	Price Target	Rating	Analyst

More analyst ratings

$CVM
Press Releases

Fastest customizable press release news feed in the world

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
Biomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration Study Patients with low PD-L1 expression treated with Multikine in the target population had a 5-year survival of 73% vs. 45% in the control group in the prior randomized controlled Phase 3 study CEL-SCI Corporation (NYSE:CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company's approach to patient selection using low PD-L1 tumor expression in its confirmatory Registration Study for Multikine® (Leukocyte Interleukin, Injection)*. This study will focus on the treatment of newly diagnosed locally adva
11/7/24 8:15:00 AM ET
$CVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
Oncologic Drugs Advisory Committee (ODAC) determines risks outweigh benefits in some cancers for frontline immune checkpoint inhibitors, including blockbuster drugs such as Keytruda and Opdivo, in patients with low PD-L1 expression Multikine has shown survival benefit and favorable safety profile in a randomized controlled Phase 3 study of treatment naïve resectable locally advanced head and neck cancer patients with low PD-L1 expression Multikine has potential as a combination drug with current checkpoint inhibitors such as Keytruda which is projected to be the top selling drug in the world with $27 billion in 2024 sales To the Company's knowledge, Multikine is the only neoadjuvant
10/22/24 9:15:00 AM ET
$CVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
As a clinical research organization (CRO) Ergomed has a strong track record with CEL-SCI in fast enrolment and high quality study delivery CEL-SCI Corporation (NYSE:CVM) today announced its renewed collaboration with Ergomed Clinical Research for its upcoming U.S. Food and Drug Administration (FDA) confirmatory Registration Study of Multikine® (Leukocyte Interleukin, Injection) in head and neck cancer. Ergomed will provide global comprehensive clinical operations support to ensure the timely and efficient execution of the trial, supporting CEL-SCI in bringing a new treatment option for patients with locally advanced primary head and neck cancer to the market. This partnership marks a con
10/1/24 6:00:00 AM ET
$CVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$CVM
Leadership Updates

Live Leadership Updates

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This
8/15/24 8:00:00 AM ET
$CVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
CEL-SCI Appoints Robert Watson as Chairperson of the Board
CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in
7/8/24 9:15:00 AM ET
$CVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation
4/23/24 9:00:00 AM ET
$CVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

CEL-SCI Appoints Robert Watson As Chairperson Of The Board
CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board.Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt instru
7/8/24 9:21:33 AM ET
$CVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
CEL-SCI Presents Head & Neck Cancer Data At IDDST Annual Congress In Budapest: Risk Of Death Cut In Half For Patients Treated With Multikine In The Target Population
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors73% survival for Multikine vs 45% in the control arm at 5 yearsStatistically significant log rank p = 0.00155-year risk of death cut in half from 55% to 27%Hazard ratio = 0.35 (95% CIs [0.19, 0.66])Working to commence FDA confirmatory Registration Study for MultikineCEL-SCI Corporation (NYSE:CVM) today announced the Company's Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled "Neoadjuvant Immunotherapy for Head and Neck Cancer: Low Tumor PD-L1 Expression - IT-MATTERS – RCT" at the International Drug Discovery Science
6/18/24 8:21:27 AM ET
$CVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
CEL-SCI Q2 2024 GAAP EPS $(0.28) Misses $(0.14) Estimate
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.14) by 100 percent.
5/16/24 9:06:11 AM ET
$CVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

CEL-SCI Appoints Robert Watson As Chairperson Of The Board

Chat with this insight

Recent Analyst Ratings for
$CVM

$CVM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Watson Robert Eugene bought $27,800 worth of shares (20,000 units at $1.39), increasing direct ownership by 451% to 24,431 units (SEC Form 4)

Prichep Patricia B bought $11,120 worth of shares (8,000 units at $1.39), increasing direct ownership by 4% to 232,326 units (SEC Form 4)

Kersten Geert R bought $41,700 worth of shares (30,000 units at $1.39), increasing direct ownership by 3% to 1,195,309 units (SEC Form 4)

$CVM
Press Releases

Fastest customizable press release news feed in the world

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

$CVM
SEC Filings

Cel-Sci Corporation filed SEC Form 8-K: Leadership Update

Cel-Sci Corporation filed SEC Form 8-K: Other Events

SEC Form EFFECT filed by Cel-Sci Corporation

$CVM
Leadership Updates

Live Leadership Updates

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results